# Study on an Optimal Antiviral Treatment in HBeAg Positive Chronic Hepatitis B Patients

> **NCT03013556** · PHASE4 · UNKNOWN · sponsor: **Ruijin Hospital** · enrollment: 180 (estimated)

## Conditions studied

- Chronic Hepatitis

## Interventions

- **DRUG:** Group A, TDF
- **DRUG:** Group B:TDF then TDF and Peginterferon alfa-2a
- **DRUG:** Group C:TDF and Peginterferon alfa-2a then TDF

## Key facts

- **NCT ID:** NCT03013556
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-11
- **Primary completion:** 2021-12-30
- **Final completion:** 2021-12-31
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2021-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03013556

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03013556, "Study on an Optimal Antiviral Treatment in HBeAg Positive Chronic Hepatitis B Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03013556. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*